Bristol Myers says FDA grants priority review to sBLA for Opdivo

Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has accepted and granted priority review to the supplemental Biologics License Application for Opdivo in combination with doxorubicin, vinblastine and dacarbazine for adult and pediatric patients with previously untreated Stage III or IV classical Hodgkin Lymphoma. The FDA assigned a Prescription Drug User Fee Act goal date of April 8, 2026. The FDA filing acceptance is based on the Phase 3 SWOG S1826 study, evaluating Opdivo in combination with AVD for adult and pediatric patients with previously untreated Stage III or IV cHL.